Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 81Carcinoma, Hepatocellular 4Neoplasms 3Carcinoma, Renal Cell 3Prostatic Diseases 2Prostate Adenocarcinoma 2Ovarian Neoplasms 2Carcinoma, Adenoid Cystic 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage II Prostate Adenocarcinoma 1Renal Insufficiency 1Prostatic Neoplasms, Castration-Resistant 1Prostate-specific Membrane Antigen 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Melanoma 1Lung Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Lobular 1

Interventions

Magnetic Resonance Spectroscopy 2prednylidene 1gallium 68 PSMA-11 1deltacortene 1apalutamide 1Prednisone 1Gonadotropin-Releasing Hormone 1BAY 86-7548 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stage II Prostate Adenocarcinoma × gallium 68 PSMA-11 × Clear all
NCT02678351 2022-03-04

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

Stanford University

Phase 2/3 Completed
74 enrolled 9 charts
Genitourinary

Stage II Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡